Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury

Journal of Korean Medical Science

Volumn 25, Issue 4, 2010, Pages 570-576

  Park, Soo Young ^a   Shin, Hye Won ^a   Lee, Kyoung Bun ^a   Lee, Min Jae ^b   Jang, Ja June ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Liver cirrhosis; Matrix metalloproteinases; Thioacetamide; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGEN; MATRIX METALLOPROTEINASE; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; EXTRACELLULAR MATRIX; GENETICS; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; COLLAGEN; EXTRACELLULAR MATRIX; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77953986092     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.4.570     Document Type: Article

References (23)

1. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995; 270: 5331-8.
2. Herbst H, Wege T, Milani S, Pellegrini G, Orzechowski HD, Bechstein WO, Neuhaus P, Gressner AM, Schuppan D. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647-59.
3. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A. Dual expression of matrix metalloproteinase-2 and membrane-type 1 matrix metalloproteinase in fibrotic human livers. Hepatology 1997; 26: 1521-9.
4. Knäuper V, Will H, Loépez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124-31.
5. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, Schadevan-Westrum S, Crabbe T, Clements J, d'Ortho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "Receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871-80.
6. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metallo-proteinases (TIMP)-2. FEBS Lett 1996; 393: 101-4.
7. Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP, Liu X, Wu H, Jaenisch R, Eeckhout Y. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem 1996; 271: 28509-15.
8. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role hepatic stellate cells. Semin Liver Dis 2001; 21: 373-84.
9. Kim TH, Mars WM, Stolz DB, Michalopoulos GK. Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology 2000; 31: 75-82.
10. Lindquist JN, Parsons CJ, Stefanovic B, Brenner DA. Regulation of α1(I) collagen messenger RNA decay by interaction with αCP at the 3'-untranslated region. J Biol Chem 2004; 279: 23822-9.
11. Nie QH, Duan GR, Luo XD, Xie YM, Luo H, Zhou YX, Pan BR. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 2004; 10: 86-90.
12. Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006; 44: 420-9.
13. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007; 46: 69-76.
14. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-7.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
16. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
17. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990; 10: 56-65.
18. Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem Res Toxicol 2005; 18: 639-54.
19. Wang CH, Lee TH, Lu CN, Chou WY, Hung KS, Concejero AM, Jawan B. Electroporative α-MSH gene transfer attenuates thioacetamide-induced murine hepatic fibrosis by MMP and TIMP modulation. Gene Therapy 2006; 13: 1000-9.
20. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21: 75-80.
21. Cheong JY, Cho SW, Lee JA, Lee KJ, Wang HJ, Lee JE, Kim JH. Matrix metalloproteinase-3 genotypes influence recovery from hepatitis B virus infection. J Korean Med Sci 2008; 23: 61-5.
22. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabró A, Ciancio G, Stefanni F. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528-37.
23. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJ. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 1992; 90: 282-7.